AXTI Insiders Trade 33 Times in Six Months as Revenue Rises to $26.9M, Loss Narrows

Key facts

• Insiders traded AXTI stock 33 times on the open market in the past six months.
• 107 institutional investors added shares in the most recent quarter; 27 reduced positions.
• Total revenue rose to $26.9 million from $19.4 million a year earlier.
• Indium phosphide generated $13.6 million in revenue; gallium arsenide $5.4 million; germanium $0.2 million; joint ventures $7.6 million.
• Asia Pacific accounted for 78% of revenue, Europe 21%, North America 1%.
• Non-GAAP gross margin improved to 29.9% from negative 6.1% a year earlier.
• Non-GAAP net loss was $0.585 million, or $0.01 per share, versus a loss of $8.2 million, or $0.19 per share, in the prior year.
• Two analysts have issued price targets with a median of $50.5.

Insider Trading Activity Signals Confidence Amid Turnaround

Insiders at AXT Inc., the California-based compound semiconductor substrate manufacturer listed on Nasdaq as $AXTI, have executed 33 open-market trades in the past six months, a flurry of activity that has drawn attention in Taiwan where the company maintains significant operations. a sharp improvement in financial performance, with revenue climbing to $26.9 million in the most recent quarter from $19.4 million a year earlier. Institutional investors have also shifted positions: 107 funds added shares in the latest quarter, while 27 reduced their holdings. The net buying suggests growing conviction that AXT's restructuring and product mix changes are gaining traction.

Revenue Growth Driven by Indium Phosphide and Asian Demand

Product revenue composition reveals the driver of the turnaround: indium phosphide substrates generated $13.6 million, gallium arsenide $5.4 million, germanium substrates just $0.2 million, and consolidated raw material joint ventures contributed $7.6 million. Indium phosphide, used in high-frequency and optoelectronic applications, now accounts for the largest single product category. Geographically, Asia Pacific delivered 78% of total revenue, Europe 21%, and North America only 1%. The heavy concentration in Asia reflects the company's strong ties to semiconductor supply chains in Taiwan, China, and other regional markets. Customer concentration remains moderate: the top five customers accounted for 32% of revenue, with none exceeding 10% individually.

Margins Recover as Operating Losses Shrink

Gross margin on a non-GAAP basis reached 29.9%, a dramatic recovery from negative 6.1% in the same period a year earlier and up from 21.5% in the preceding quarter. GAAP gross margin followed a similar trajectory, rising to 29.6% from negative 6.4%. The improvement reflects higher revenue, better product mix, and cost controls. Non-GAAP operating expenses totaled $8.6 million, compared with $8.5 million a year earlier and $7.5 million in the prior quarter. The non-GAAP operating loss narrowed to $0.55 million from $9.6 million a year ago, while the GAAP operating loss improved to $1.6 million from $10.3 million. Net loss on a non-GAAP basis came in at $0.585 million, or $0.01 per share, versus a loss of $8.2 million, or $0.19 per share, in the year-ago period.

Analyst Price Targets and Market Sentiment

Two analysts have issued price targets for AXT in the past six months, with a median target of $50.5. The stock's recent insider buying, combined with institutional accumulation, suggests that market participants see the narrowing losses as a precursor to sustained profitability. However, the company still faces headwinds: the germanium substrate business remains negligible, and the reliance on Asia Pacific exposes it to geopolitical and supply-chain risks. The company has not provided forward guidance, but the sequential improvement in margins and revenue indicates that the restructuring efforts initiated over the past two years are beginning to bear fruit. Investors will be watching whether the indium phosphide segment can maintain its momentum and whether the gallium arsenide business can recover.

Outlook: Path to Profitability Hinges on Indium Phosphide and Cost Discipline

AXT's path to sustained profitability depends on continued growth in indium phosphide sales and strict cost management. The non-GAAP operating loss of just $0.55 million is close to breakeven, and the company has demonstrated that it can scale revenue while controlling expenses. The $26.9 million revenue figure, up from $23.0 million in the prior quarter and $19.4 million a year earlier, shows a clear upward trend. Yet the company remains a small player in a capital-intensive industry. The heavy insider trading activity — 33 trades in six months — may reflect management's confidence, but it also raises questions about the timing and motivation behind the transactions. With a median analyst price target of $50.5, the market is pricing in a significant recovery. Whether AXT can deliver on that promise will depend on its ability to maintain margin improvement and navigate the volatile semiconductor cycle.

The bottom line

• AXT insiders have traded the stock 33 times in six months, and 107 institutions added shares in the latest quarter.
• Revenue rose to $26.9 million, driven by indium phosphide sales of $13.6 million.
• Non-GAAP gross margin improved to 29.9% from negative 6.1% a year earlier.
• Non-GAAP net loss narrowed to $0.585 million, or $0.01 per share, from $8.2 million, or $0.19 per share.
• Asia Pacific contributed 78% of revenue; top five customers accounted for 32%.
• Two analysts have a median price target of $50.5, implying significant upside from current levels.